224 related articles for article (PubMed ID: 31760648)
61. Baló's concentric sclerosis: surviving normal myelin in a patient with a relapsing-remitting dinical course.
Moore GR; Berry K; Oger JJ; Prout AJ; Graeb DA; Nugent RA
Mult Scler; 2001 Dec; 7(6):375-82. PubMed ID: 11795459
[TBL] [Abstract][Full Text] [Related]
62. Inflammatory demyelinating polyradiculitis in a patient with multiple sclerosis.
Lassmann H; Budka H; Schnaberth G
Arch Neurol; 1981 Feb; 38(2):99-102. PubMed ID: 7469845
[TBL] [Abstract][Full Text] [Related]
63. Imaging of CNS myelin by positron-emission tomography.
Stankoff B; Wang Y; Bottlaender M; Aigrot MS; Dolle F; Wu C; Feinstein D; Huang GF; Semah F; Mathis CA; Klunk W; Gould RM; Lubetzki C; Zalc B
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9304-9. PubMed ID: 16754874
[TBL] [Abstract][Full Text] [Related]
64. A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination.
Merkler D; Ernsting T; Kerschensteiner M; Brück W; Stadelmann C
Brain; 2006 Aug; 129(Pt 8):1972-83. PubMed ID: 16714315
[TBL] [Abstract][Full Text] [Related]
65. Remyelination strategies in multiple sclerosis: a critical reflection.
Kipp M
Expert Rev Neurother; 2016; 16(1):1-3. PubMed ID: 26618372
[TBL] [Abstract][Full Text] [Related]
66. Central nervous system demyelination and remyelination in multiple sclerosis and viral models of disease.
Rodriguez M
J Neuroimmunol; 1992 Oct; 40(2-3):255-63. PubMed ID: 1430155
[TBL] [Abstract][Full Text] [Related]
67. Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination.
Mohan H; Friese A; Albrecht S; Krumbholz M; Elliott CL; Arthur A; Menon R; Farina C; Junker A; Stadelmann C; Barnett SC; Huitinga I; Wekerle H; Hohlfeld R; Lassmann H; Kuhlmann T; Linington C; Meinl E
Acta Neuropathol Commun; 2014 Dec; 2():168. PubMed ID: 25589163
[TBL] [Abstract][Full Text] [Related]
68. Roads to Formation of Normal Myelin Structure and Pathological Myelin Structure.
Bando Y
Adv Exp Med Biol; 2019; 1190():257-264. PubMed ID: 31760649
[TBL] [Abstract][Full Text] [Related]
69. Role of Oligodendrocyte Dysfunction in Demyelination, Remyelination and Neurodegeneration in Multiple Sclerosis.
Dulamea AO
Adv Exp Med Biol; 2017; 958():91-127. PubMed ID: 28093710
[TBL] [Abstract][Full Text] [Related]
70. Novel monoclonal antibodies against proteolipid protein peptide 139-151 demonstrate demyelination and myelin uptake by macrophages in MS and marmoset EAE lesions.
Laman JD; Visser L; Maassen CB; de Groot CJ; de Jong LA; 't Hart BA; van Meurs M; Schellekens MM
J Neuroimmunol; 2001 Sep; 119(1):124-30. PubMed ID: 11525809
[TBL] [Abstract][Full Text] [Related]
71. Biotherapies in multiple sclerosis: a step toward remyelination and neuroprotection?
Dubessy AL; Zujovic V; Papeix C; Stankoff B
Rev Neurol (Paris); 2014 Dec; 170(12):770-8. PubMed ID: 25459127
[TBL] [Abstract][Full Text] [Related]
72. Neuroimaging of demyelination and remyelination models.
Pirko I; Johnson AJ
Curr Top Microbiol Immunol; 2008; 318():241-66. PubMed ID: 18219821
[TBL] [Abstract][Full Text] [Related]
73. GD1a Overcomes Inhibition of Myelination by Fibronectin via Activation of Protein Kinase A: Implications for Multiple Sclerosis.
Qin J; Sikkema AH; van der Bij K; de Jonge JC; Klappe K; Nies V; Jonker JW; Kok JW; Hoekstra D; Baron W
J Neurosci; 2017 Oct; 37(41):9925-9938. PubMed ID: 28899916
[TBL] [Abstract][Full Text] [Related]
74. A new myelin protein, TPPP/p25, reduced in demyelinated lesions is enriched in cerebrospinal fluid of multiple sclerosis.
Vincze O; Oláh J; Zádori D; Klivényi P; Vécsei L; Ovádi J
Biochem Biophys Res Commun; 2011 May; 409(1):137-41. PubMed ID: 21565174
[TBL] [Abstract][Full Text] [Related]
75. Correlation between vitamin D and alterations in MRI among patients with multiple sclerosis.
Piędel F; Rocka A; Piwek M; Jasielski PP; Petit V; Rejdak K
Ann Agric Environ Med; 2021 Sep; 28(3):372-377. PubMed ID: 34558256
[TBL] [Abstract][Full Text] [Related]
76. [Novel remyelination strategy for multiple sclerosis in the era of oligodendrocytopathy].
Nakahara J
Rinsho Shinkeigaku; 2012; 52(11):1351-3. PubMed ID: 23196615
[TBL] [Abstract][Full Text] [Related]
77. Proteolipid protein gene expression in demyelination and remyelination of the central nervous system: a model for multiple sclerosis.
Rodriguez M; Prayoonwiwat N; Howe C; Sanborn K
J Neuropathol Exp Neurol; 1994 Mar; 53(2):136-43. PubMed ID: 7509847
[TBL] [Abstract][Full Text] [Related]
78. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis.
Schmierer K; Parkes HG; So PW; An SF; Brandner S; Ordidge RJ; Yousry TA; Miller DH
Brain; 2010 Mar; 133(Pt 3):858-67. PubMed ID: 20123726
[TBL] [Abstract][Full Text] [Related]
79. Spontaneous remyelination in lesions protects the integrity of surrounding tissues over time in multiple sclerosis.
Ricigliano VAG; Tonietto M; Hamzaoui M; Poirion É; Lazzarotto A; Bottlaender M; Gervais P; Maillart E; Stankoff B; Bodini B
Eur J Neurol; 2022 Jun; 29(6):1719-1729. PubMed ID: 35152511
[TBL] [Abstract][Full Text] [Related]
80. Myelin transcription factor 1 (Myt1) expression in demyelinated lesions of rodent and human CNS.
Vana AC; Lucchinetti CF; Le TQ; Armstrong RC
Glia; 2007 May; 55(7):687-97. PubMed ID: 17330875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
